Understanding the cellular uptake and intracellular trafficking of oligonucleotides provides an important basic underpinning for the developing field of oligonucleotide-based therapeutics. Whether delivered as “free” oligonucleotides, as ligand–oligonucleotide conjugates, or in association with various nanocarriers, all forms of oligonucleotide enter cells by endocytosis and are initially ensconced within membrane-limited vesicles. Accordingly, the locus and extent of release to the cytosol and nucleus are key determinants of the pharmacological actions of oligonucleotides. A number of recent studies have explored the intracellular trafficking of various forms of oligonucleotides and their release from endomembrane compartments. These studies reveal a surprising convergence on an early-intermediate compartment in the trafficking pathway as the key locus of release for oligonucleotides administered in “free” form as well as those delivered with lipid complexes. Thus, oligonucleotide release from multivesicular bodies or from late endosomes seems to be the crucial endogenous process for attaining pharmacological effects. This intrinsic process of oligonucleotide release may be amplified by delivery agents such as lipid complexes or small molecule enhancers.
Get full access to this article
View all access options for this article.
References
1.
BennettCF, BakerBF, PhamN, SwayzeE and GearyRS. (2017). Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol, 57:81–105.
2.
BobbinML and RossiJJ. (2016). RNA interference (RNAi)-based therapeutics: delivering on the Promise?. Annu Rev Pharmacol Toxicol, 56:103–122.
3.
WuSY, Lopez-BeresteinG, CalinGA and Sood.AK (2014). RNAi therapies: drugging the undruggable. Sci Transl Med, 6:240ps7.
4.
KoleR, KrainerAR and AltmanS. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov, 11:125–140.
5.
SteinCA and CastanottoD. (2017). FDA-approved oligonucleotide therapies in 2017. Mol Ther, 25:1069–1075.
6.
CrookeST, WangS, VickersTA, ShenW and LiangXH. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol, 35:230–237.
JulianoRL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res, 44:6518–6548.
9.
LorenzerC, DirinM, WinklerAM, BaumannV and WinklerJ. (2015). Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release, 203:1–15.
10.
YinH, KanastyRL, EltoukhyAA, VegasAJ, DorkinJR and AndersonDG. (2014). Non-viral vectors for gene-based therapy. Nat Rev Genet, 15:541–555.
11.
WattsJK and CoreyDR. (2012). Silencing disease genes in the laboratory and the clinic. J Pathol, 226:365–379.
12.
WickstromE. (2015). DNA and RNA derivatives to optimize distribution and delivery. Adv Drug Deliv Rev, 87:25–34.
13.
JulianoRL, MingX and NakagawaO. (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem, 23:147–157.
14.
VarkouhiAK, ScholteM, StormG and HaismaHJ. (2011). Endosomal escape pathways for delivery of biologicals. J Control Release, 151:220–228.
15.
JulianoRL and CarverK. (2015). Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev, 87:35–45.
16.
WittrupA and LiebermanJ. (2015). Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet, 16:543–552.
17.
DohertyGJ and McMahonHT. (2009). Mechanisms of endocytosis. Annu Rev Biochem, 78:857–902.
HuotariJ and HeleniusA. (2011). Endosome maturation. EMBO J, 30:3481–3500.
20.
JohannesL and WunderC. (2011). Retrograde transport: two (or more) roads diverged in an endosomal tree?. Traffic, 12:956–962.
21.
HansonPI and CashikarA. (2012). Multivesicular body morphogenesis. Annu Rev Cell Dev Biol, 28:337–362.
22.
ScottCC, VaccaF and GruenbergJ. (2014). Endosome maturation, transport and functions. Semin Cell Dev Biol, 31:2–10.
23.
LuzioJP, PryorPR and BrightNA. (2007). Lysosomes: fusion and function. Nat Rev Mol Cell Biol, 8:622–632.
24.
KlumpermanJ and Raposo.G (2014). The complex ultrastructure of the endolysosomal system. Cold Spring Harb Perspect Biol, 6:a016857.
25.
CaiH, ReinischK and Ferro-NovickS. (2007). Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev Cell, 12:671–682.
26.
MayorS, PartonRG and DonaldsonJG. (2014). Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol, 6:pii: a016758.
27.
BonifacinoJS and NeefjesJ. (2017). Moving and positioning the endolysosomal system. Curr Opin Cell Biol, 47:1–8.
28.
SpangA. (2016). Membrane tethering complexes in the endosomal system. Front Cell Dev Biol, 4:35.
29.
WitkosTM and LoweM. (2017). Recognition and tethering of transport vesicles at the Golgi apparatus. Curr Opin Cell Biol, 47:16–23.
30.
KummelD and UngermannC. (2014). Principles of membrane tethering and fusion in endosome and lysosome biogenesis. Curr Opin Cell Biol, 29:61–66.
KurrikoffK, GestinM and LangelU. (2016). Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opin Drug Deliv, 13:373–387.
42.
LindbergS, RegbergJ, ErikssonJ, HelmforsH, Munoz-AlarconA, SrimaneeA, FigueroaRA, HallbergE, EzzatK and LangelU. (2015). A convergent uptake route for peptide- and polymer-based nucleotide delivery systems. J Control Release, 206:58–66.
43.
ElouahabiA and RuysschaertJM. (2005). Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther, 11:336–347.
44.
MingX, SatoK and JulianoRL. (2011). Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release, 153:83–92.
45.
HassaneFS, AbesR, El AndaloussiS, LehtoT, SillardR, LangelU and LebleuB. (2011). Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release, 153:163–172.
46.
RehmanZ, HoekstraD and ZuhornIS. (2013). Mechanism of polyplex- and lipoplex-mediated delivery of nucleic acids: real-time visualization of transient membrane destabilization without endosomal lysis. ACS Nano, 7:3767–3777.
47.
WangC, de JongE, SjollemaKA and Zuhorn.IS (2016). Entry of PIP3-containing polyplexes into MDCK epithelial cells by local apical-basal polarity reversal. Sci Rep, 6:21436.
48.
LazebnikM and PackDW. (2017). Rapid and facile quantitation of polyplex endocytic trafficking. J Control Release, 247:19–27.
49.
ShuklaRS, JainA, ZhaoZ and ChengK. (2016). Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex. Nanomedicine, 12:1323–1334.
50.
EltoukhyAA, SahayG, CunninghamJM and AndersonDG. (2014). Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles. ACS Nano, 8:7905–7913.
51.
SongW, MaZ, ZhangY and YangC. (2017). Autophagy plays a dual role during intracellular siRNA delivery by lipoplex and polyplex nanoparticles. Acta Biomater, 58:196–204.
52.
ZhongX, PanusD, JiW and WangC. (2015). Modulating polyplex-mediated gene transfection by small-molecule regulators of autophagy. Mol Pharm, 12:932–940.
53.
BarnabySN, SitaTL, PetroskoSH, SteghAH and MirkinCA. (2015). Therapeutic applications of spherical nucleic acids. Cancer Treat Res, 166:23–50.
54.
JensenSA, DayES, KoCH, HurleyLA, LucianoJP, KouriFM, MerkelTJ, LuthiAJ, PatelPC, et al. (2013). Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med, 5:209ra152.
55.
WuXA, ChoiCH, ZhangC, HaoL and MirkinCA. (2014). Intracellular fate of spherical nucleic acid nanoparticle conjugates. J Am Chem Soc, 136:7726–7733.
56.
LiJ, FanC, PeiH, ShiJ and HuangQ. (2013). Smart drug delivery nanocarriers with self-assembled DNA nanostructures. Adv Mater, 25:4386–4396.
57.
LeeH, Lytton-JeanAK, ChenY, LoveKT, ParkAI, KaragiannisED, SehgalA, QuerbesW, ZurenkoCS, et al. (2012). Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol, 7:389–393.
58.
LiangL, LiJ, LiQ, HuangQ, ShiJ, YanH and FanC. (2014). Single-particle tracking and modulation of cell entry pathways of a tetrahedral DNA nanostructure in live cells. Angew Chem Int Ed Engl, 53:7745–7750.
59.
SteinCA, HansenJB, LaiJ, WuS, VoskresenskiyA, HogA, WormJ, HedtjarnM, SouleimanianN, et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res, 38:e3.
60.
KollerE, VincentTM, ChappellA, DeS, ManoharanM and BennettCF. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res, 39:4795–4807.
61.
WangS, SunH, TanowitzM, LiangXH and CrookeST. (2016). Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. Nucleic Acids Res, 44:7314–7330.
62.
WangS, SunH, TanowitzM, LiangXH and CrookeST. (2017). Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res, 45:5309–5322.
63.
WagenaarTR, TolstykhT, ShiC, JiangL, ZhangJ, LiZ, YuQ, QuH, SunF, et al. (2015). Identification of the endosomal sorting complex required for transport-I (ESCRT-I) as an important modulator of anti-miR uptake by cancer cells. Nucleic Acids Res, 43:1204–1215.
64.
Erazo-OliverasA, NajjarK, TruongD, WangTY, BrockDJ, PraterAR and PelloisJP. (2016). The late endosome and its lipid BMP act as gateways for efficient cytosolic access of the delivery agent dfTAT and its macromolecular cargos. Cell Chem Biol, 23:598–607.
65.
CastanottoD, LinM, KowolikC, WangL, RenXQ, SoiferHS, KochT, HansenBR, OerumH, et al. (2015). A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Nucleic Acids Res, 43:9350–9361.
66.
CastanottoD, LinM, KowolikC, KochT, HansenBR, OerumH and SteinCA. (2016). Protein Kinase C-alpha is a critical protein for antisense oligonucleotide-mediated silencing in mammalian cells. Mol Ther, 24:1117–1125.
67.
Gonzalez-BarrigaA, NillessenB, KranzenJ, van KesselIDG, CroesHJE, AguileraB, de VisserPC, DatsonNA, MuldersSAM, et al. (2017). Intracellular distribution and nuclear activity of antisense oligonucleotides after unassisted uptake in myoblasts and differentiated myotubes in vitro. Nucleic Acid Ther, 27:144–158.
68.
LiangXH, SunH, NicholsJG and CrookeST. (2017). RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther, 25:2075–2092.
69.
NairJK, WilloughbyJL, ChanA, CharisseK, AlamMR, WangQ, HoekstraM, KandasamyP, Kel'inAV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc, 136:16958–16961.
70.
HuangY. (2017). Preclinical and clinical advances of galnac-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids, 6:116–132.
71.
TanowitzM, HettrickL, RevenkoA, KinbergerGA, PrakashTP and SethPP. (2017). Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res, 45:12388–12400.
72.
MeadeBR, GogoiK, HamilAS, Palm-ApergiC, van den BergA, HagopianJC, SpringerAD, EguchiA, KacsintaAD, et al. (2014). Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol, 32:1256–1261.
73.
AlamMR, DixitV, KangH, LiZB, ChenX, TrejoJ, FisherM and JulianoRL. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res, 36:2764–2776.
74.
MingX, AlamMR, FisherM, YanY, ChenX and JulianoRL. (2010). Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res, 38:6567–6576.
75.
AlamMR, MingX, DixitV, FisherM, ChenX and JulianoRL. (2010). The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides, 20:103–109.
76.
AlamMR, MingX, FisherM, LackeyJG, RajeevKG, ManoharanM and JulianoRL. (2011). Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem, 22:1673–1681.
77.
KortylewskiM, SwiderskiP, HerrmannA, WangL, KowolikC, KujawskiM, LeeH, ScutoA, LiuY, et al. (2009). In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol, 27:925–932.
BoisguerinP, DeshayesS, GaitMJ, O'DonovanL, GodfreyC, BettsCA, WoodMJ and LebleuB. (2015). Delivery of therapeutic oligonucleotides with cell penetrating peptides. Adv Drug Deliv Rev, 87:52–67.
80.
LehtoT, EzzatK, WoodMJA and El AndaloussiS. (2016). Peptides for nucleic acid delivery. Adv Drug Deliv Rev, 106:172–182.
81.
RinaldiC and WoodMJA. (2018). Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol, 14:9–21.
82.
AbesS, MoultonHM, ClairP, PrevotP, YoungbloodDS, WuRP, IversenPL and LebleuB. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release, 116:304–313.
83.
LehtoT, Castillo AlvarezA, GauckS, GaitMJ, CoursindelT, WoodMJ, LebleuB and BoisguerinP. (2014). Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res, 42:3207–3217.
84.
MingX, CarverK, FisherM, NoelR, CintratJC, GilletD, BarbierJ, CaoC, BaumanJ and JulianoRL. (2013). The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res, 41:3673–3687.
85.
YangB, MingX, CaoC, LaingB, YuanA, PorterMA, Hull-RydeEA, MaddryJ, SutoM, JanzenWP and JulianoRL. (2015). High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res, 43:1987–1996.
86.
WangL, AriyarathnaY, MingX, YangB, JamesLI, KredaSM, PorterM, JanzenW and JulianoRL. (2017). A novel family of small molecules that enhance the intracellular delivery and pharmacological effectiveness of antisense and splice switching oligonucleotides. ACS Chem Biol, 12:1999–2007.
87.
ZhangX, CastanottoD, NamS, HorneD and SteinC. (2017). 6BIO enhances oligonucleotide activity in cells: a potential combinatorial anti-androgen receptor therapy in prostate cancer cells. Mol Ther, 25:79–91.
88.
OsbornMF, AltermanJF, NikanM, CaoH, DidiotMC, HasslerMR, ColesAH and KhvorovaA. (2015). Guanabenz (Wytensin) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res, 43:8664–8672.
89.
GilleronJ, ParamasivamP, ZeigererA, QuerbesW, MarsicoG, AndreeC, SeifertS, AmayaP, StoterM, et al. (2015). Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res, 43:7984–8001.
90.
JulianoRL, WangL, TavaresF, BrownEG, JamesL, AriyarathnaY, MingX, MaoC and SutoM. (2018). Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides. Nucleic Acids Res, 46:1601–1613.
91.
BaileyJK, ShenW, LiangXH and CrookeST. (2017). Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides. Nucleic Acids Res, 45:10649–10671.
92.
LiangXH, ShenW, SunH, KinbergerGA, PrakashTP, NicholsJG and CrookeST. (2016). Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity. Nucleic Acids Res, 44:3892–3907.
93.
LiangXH, ShenW, SunH, PrakashTP and CrookeST. (2014). TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acids Res, 42:7819–7832.
94.
KobayashiT, StangE, FangKS, de MoerlooseP, PartonRG and GruenbergJ. (1998). A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature, 392:193–197.
95.
WangT, SmithEA, ChapmanER and WeisshaarJC. (2009). Lipid mixing and content release in single-vesicle, SNARE-driven fusion assay with 1–5 ms resolution. Biophys J, 96:4122–4131.
96.
SudhofTC and RothmanJE. (2009). Membrane fusion: grappling with SNARE and SM proteins. Science, 323:474–477.
97.
RenardHF, JohannesL and MorsommeP. (2018). Increasing diversity of biological membrane fission mechanisms. Trends Cell Biol, 28:274–286.
98.
WicknerW and RizoJ. (2017). A cascade of multiple proteins and lipids catalyzes membrane fusion. Mol Biol Cell, 28:707–711.
99.
BennettWF and TielemanDP. (2014). The importance of membrane defects-lessons from simulations. Acc Chem Res, 47:2244–2251.
100.
CullisPR, HopeMJ and TilcockCP. (1986). Lipid polymorphism and the roles of lipids in membranes. Chem Phys Lipids, 40:127–144.
101.
ZelphatiO and SzokaFCJr. (1996). Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A, 93:11493–11498.
102.
GallonM and CullenPJ. (2015). Retromer and sorting nexins in endosomal sorting. Biochem Soc Trans, 43:33–47.
103.
HenneWM, StenmarkH and EmrSD. (2013). Molecular mechanisms of the membrane sculpting ESCRT pathway. Cold Spring Harb Perspect Biol, 5: pii: a016766.
104.
DoresMR and TrejoJ. (2014). Atypical regulation of G protein-coupled receptor intracellular trafficking by ubiquitination. Curr Opin Cell Biol, 27:44–50.
105.
KobayashiT, StartchevK, WhitneyAJ and GruenberJ. (2001). Localization of lysobisphosphatidic acid-rich membrane domains in late endosomes. Biol Chem, 382:483–485.
106.
BissigC and GruenbergJ. (2014). ALIX and the multivesicular endosome: ALIX in Wonderland. Trends Cell Biol, 24:19–25.
107.
EdgarJR, EdenER and FutterCE. (2014). Hrs- and CD63-dependent competing mechanisms make different sized endosomal intraluminal vesicles. Traffic, 15:197–211.
108.
MatsuoH, ChevallierJ, MayranN, Le BlancI, FergusonC, FaureJ, BlancNS, MatileS, DubochetJ, et al. (2004). Role of LBPA and Alix in multivesicular liposome formation and endosome organization. Science, 303:531–534.
109.
SeguraV, Perez-AsoM, MontoF, CarcellerE, NogueraMA, PedianiJ, MilliganG, McGrathIC and D'OconP. (2013). Differences in the signaling pathways of alpha(1A)- and alpha(1B)-adrenoceptors are related to different endosomal targeting. PLoS One, 8:e64996.
110.
GrimmD, StreetzKL, JoplingCL, StormTA, PandeyK, DavisCR, MarionP, SalazarF and KayMA. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 441:537–541.
